These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 23435031)
1. Dehydroepiandrosterone sulfate levels reflect endogenous luteinizing hormone production and response to human chorionic gonadotropin challenge in older female macaque (Macaca fascicularis). Moran FM; Chen J; Gee NA; Lohstroh PN; Lasley BL Menopause; 2013 Mar; 20(3):329-35. PubMed ID: 23435031 [TBL] [Abstract][Full Text] [Related]
2. Effects of subchronic infusion of dehydroepiandrosterone sulfate on serum gonadotropin levels and ovarian function in the cynomolgus monkey. Kowalski W; Chatterton RT Fertil Steril; 1992 Apr; 57(4):912-20. PubMed ID: 1532562 [TBL] [Abstract][Full Text] [Related]
4. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction. Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463 [TBL] [Abstract][Full Text] [Related]
5. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin. Fraser HM; Nestor JJ; Vickery BH Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885 [TBL] [Abstract][Full Text] [Related]
6. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867 [TBL] [Abstract][Full Text] [Related]
10. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome. Gonzalez F; Hatala DA; Speroff L Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519 [TBL] [Abstract][Full Text] [Related]
11. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease. de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501 [TBL] [Abstract][Full Text] [Related]
12. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285 [TBL] [Abstract][Full Text] [Related]
14. Effects of gonadotropin-releasing hormone agonist on human chorionic gonadotropin activity in granulosa cells of immature female rats. Tungmahasuk D; Fungbun N; Laoharatchatathanin T; Terashima R; Kurusu S; Kawaminami M J Reprod Dev; 2018 Apr; 64(2):129-134. PubMed ID: 29249775 [TBL] [Abstract][Full Text] [Related]
15. Functional luteinizing hormone/chorionic gonadotropin receptors in human adrenal cortical H295R cells. Rao ChV; Zhou XL; Lei ZM Biol Reprod; 2004 Aug; 71(2):579-87. PubMed ID: 15084485 [TBL] [Abstract][Full Text] [Related]
16. Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism. Castelo-Branco C; Martínez de Osaba MJ; Martínez S; Fortuny A Metabolism; 1996 Jan; 45(1):24-7. PubMed ID: 8544772 [TBL] [Abstract][Full Text] [Related]
17. Administration of human luteinizing hormone (hLH) to macaques after follicular development: further titration of LH surge requirements for ovulatory changes in primate follicles. Zelinski-Wooten MB; Hutchison JS; Chandrasekher YA; Wolf DP; Stouffer RL J Clin Endocrinol Metab; 1992 Aug; 75(2):502-7. PubMed ID: 1639951 [TBL] [Abstract][Full Text] [Related]
18. Effects of dibutyryl adenosine 3',5'-monophosphate, luteinizing hormone-releasing hormone, and aromatase inhibitor on simultaneous outputs of progesterone, 17 beta-estradiol, and human chorionic gonadotropin by term placental explants. Haning RV; Choi L; Kiggens AJ; Kuzma DL; Summerville JW J Clin Endocrinol Metab; 1982 Aug; 55(2):213-8. PubMed ID: 6282920 [TBL] [Abstract][Full Text] [Related]
19. The pituitary-gonadal axis in women with benign or malignant ovarian tumors. Blaakaer J; Djursing H; Hørding U; Bennett P; Toftager-Larsen K; Bock JE; Lebech PE Acta Endocrinol (Copenh); 1992 Aug; 127(2):127-30. PubMed ID: 1388313 [TBL] [Abstract][Full Text] [Related]
20. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration. Dubourdieu S; Charbonnel B; Massai MR; Marraoui J; Spitz I; Bouchard P Fertil Steril; 1991 Sep; 56(3):440-5. PubMed ID: 1894021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]